Search results

Skip to results

Type

Type

Last updated

Last updated

Guidance programme

Your search for ���������������������������������������:za33��������������� returned no results
Showing 1 result for ���������������������������������������:ta33���������������

  1. The clinical effectiveness and cost effectiveness of irinotecan, oxaliplatin and raltitrexed for colorectal cancer (TA33)

    This guidance has been replaced by NICE technology appraisal guidance 93 [Replaced by NICE guideline CG131].

    Technology appraisal guidance
    Published
    27 March 2002